文献速递神经肿瘤

脑膜瘤分子亚群与肿瘤复发的关联

Associations of meningioma molecular subgroup and tumor recurrence.
PubMed 文献 · Neuro Oncol · 2021-01-01

该研究分析了469例已知分子亚群脑膜瘤的结局数据,包括切除范围、术后放疗、监测影像和复发时间。结果显示不同分子亚群临床病程差异显著,NF2、PI3K、HH、TRAF7等侵袭性亚群2年复发率平均为KLF4、POLR2A、SMARCB1等亚群的22倍,分子亚群是复发的独立预测因子。

要点

  • 脑膜瘤分子亚群与复发风险独立相关,应纳入术后管理决策。
  • NF2、PI3K、HH、TRAF7亚群复发率显著高于KLF4、POLR2A、SMARCB1亚群。
  • 低级别脑膜瘤中HH和TRAF7亚群复发率也升高。

核心结论

  • 脑膜瘤分子亚群与不同临床结局和复发率相关,分子亚群是复发的独立预测因子。
  • 基因组特征对指导脑膜瘤术后管理决策具有重要性。

研究设计与样本

  • 回顾性分析469例已知分子亚群脑膜瘤的结局数据,包括切除范围、术后放疗、监测影像和复发时间。
  • 采用Kaplan-Meier分析比较无进展生存,Cox比例风险模型识别复发相关因素。

主要发现

  • 中位随访2年时,NF2、PI3K、HH、TRAF7等侵袭性亚群平均复发率为KLF4、POLR2A、SMARCB1亚群的22倍。
  • PI3K激活肿瘤复发早于其他亚群,但长期结局中等。
  • 低级别肿瘤中,HH和TRAF7脑膜瘤复发率高于其他亚群。
  • NF2肿瘤复发与男性、高级别和Ki-67升高相关。
  • 多变量分析显示分子亚群、分级和既往复发是复发的独立预测因子。

临床怎么用

  • 术后管理决策应考虑脑膜瘤分子亚群,对侵袭性亚群加强监测。
  • NF2、PI3K、HH、TRAF7亚群患者可能需更密切随访或辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We and others have identified mutually exclusive molecular subgroups of meningiomas; however, the implications of this classification for clinical prognostication remain unclear. Integrated genomic and epigenomic analyses implicate unique oncogenic processes associated with each subgroup, suggesting the potential for divergent clinical courses. The aim of this study was to understand the associated clinical outcomes of each subgroup, as this could optimize treatment for patients. METHODS: We analyzed outcome data for 469 meningiomas of known molecular subgroup, including extent of resection, postoperative radiation, surveillance imaging, and time to recurrence, when applicable. Statistical relationships between outcome variables and subgroup were assessed. Features previously associated with recurrence were further investigated after stratification by subgroup. We used Kaplan-Meier analyses to compare progression-free survival, and identified factors significantly associated with recurrence using Cox proportional hazards modeling. RESULTS: Meningioma molecular subgroups exhibited divergent clinical courses at 2 years of follow-up, with several aggressive subgroups (NF2, PI3K, HH, tumor necrosis factor receptor-associated factor 7 [TRAF7]) recurring at an average rate of 22 times higher than others (KLF4, POLR2A, SMARCB1). PI3K-activated tumors recurred earlier than other subgroups but had intermediate long-term outcome. Among low-grade tumors, HH and TRAF7 meningiomas exhibited elevated recurrence compared with other subgroups. Recurrence of NF2 tumors was associated with male sex, high grade, and elevated Ki-67. Multivariate analysis identified molecular subgroup as an independent predictor of recurrence, along with grade and previous recurrence. CONCLUSION: We describe distinct clinical outcomes and recurrence rates associated with meningioma molecular subgroups. Our findings emphasize the importance of genomic characterization to guide postoperative management decisions for meningiomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Youngblood MW, Miyagishima DF, Jin L, et al. Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol. 2021. PMID: 33068421. doi:10.1093/neuonc/noaa226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。